METHODS: This randomized double-blind placebo-controlled clinical trial was conducted in 42 patients with CSFP (age 35-70 years, 25 ≤ body mass index < 40 kg/m2). Patients received either 80 mg/day nano-curcumin or placebo for 12 weeks. Serum levels of visfatin, high-sensitivity C-reactive protein (hs-CRP), and glycemic indices were measured before and after the intervention. The short form 36-item quality of life (SF-36) and Beck\'s Depression Inventory-II (BDI-II) questionnaires were assessed, as well.
RESULTS: No significant improvements were observed in circulating hs-CRP and visfatin following the intervention. A significant increase was observed in pre- to post-fasting blood glucose (- 0.9 ± 12.2 vs. 7.7 ± 12.4 mg/dl, p = 0.02) and hemoglobin A1C (- 0.1 ± 0.8 vs. 0.5 ± 0.8%, p = 0.04) levels, in the placebo compared with the intervention group. Physical (8.2 ± 8.1 vs. - 1.2 ± 6.5, p < 0.001) and mental (6.8 ± 11.8 vs. - 1.1 ± 10.4, p = 0.02) component summary scores were significantly improved in the nano-curcumin than the placebo group. Additionally, the number of patients with lower degrees of depression was significantly better in the intervention than the placebo group following the supplementation (p = 0.046).
CONCLUSIONS: Curcumin supplementation prevented deterioration of glycemic control and improved physical and psychological quality of life and depression in patients with CSFP.
BACKGROUND: Iranian Registry of Clinical Trials (IRCT20131125015536N8), June 19, 2019.
方法:这项随机双盲安慰剂对照临床试验在42名CSFP患者中进行(年龄35-70岁,25≤体重指数<40kg/m2)。患者接受80毫克/天的纳米姜黄素或安慰剂治疗12周。血清内脂素水平,高敏C反应蛋白(hs-CRP),在干预前后测量血糖指数。简表36项生活质量(SF-36)和贝克抑郁量表-II(BDI-II)问卷进行评估,也是。
结果:干预后,循环hs-CRP和内脂素没有显著改善。空腹前后血糖显着增加(-0.9±12.2vs.7.7±12.4mg/dl,p=0.02)和血红蛋白A1C(-0.1±0.8vs.0.5±0.8%,p=0.04)水平,与干预组相比,安慰剂组。物理(8.2±8.1vs.-1.2±6.5,p<0.001)和精神(6.8±11.8vs.-1.1±10.4,p=0.02)纳米姜黄素组的成分汇总得分比安慰剂组显着提高。此外,在补充药物后,干预组抑郁程度较低的患者数量明显优于安慰剂组(p=0.046).
结论:补充姜黄素可以防止CSFP患者血糖控制恶化,并改善其生理和心理生活质量和抑郁。
背景:伊朗临床试验注册(IRCT20131125015536N8),2019年6月19日。